Kurs
-0,31%
Kurs
-0,31%
Open
25,48
High
25,62
Low
24,80
Close
25,34
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
10,9 MNOK
Likviditet
10,9 MNOK
Rel. mcap
1,21%
Antal aktier
430 027
Likviditet under dagen för detta pressmeddelande
Kalender
Tid* | ||
2026-02-25 | 06:30 | Bokslutskommuniké 2025 |
2025-11-26 | 00:00 | Kvartalsrapport 2025-Q3 |
2025-08-20 | 00:00 | Kvartalsrapport 2025-Q2 |
2025-05-22 | N/A | Årsstämma |
2025-05-14 | 00:00 | Kvartalsrapport 2025-Q1 |
2025-02-26 | 06:30 | Bokslutskommuniké 2024 |
2024-11-27 | - | Kvartalsrapport 2024-Q3 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2024-05-16 | - | Årsstämma |
2024-05-14 | - | Kvartalsrapport 2024-Q1 |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-11-15 | - | Kvartalsrapport 2023-Q3 |
2023-08-23 | - | Kvartalsrapport 2023-Q2 |
2023-05-16 | - | Kvartalsrapport 2023-Q1 |
2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2023-05-11 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-11-23 | - | Kvartalsrapport 2022-Q3 |
2022-08-24 | - | Kvartalsrapport 2022-Q2 |
2022-05-16 | - | Kvartalsrapport 2022-Q1 |
2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2022-05-12 | - | Årsstämma |
2022-03-31 | - | Bokslutskommuniké 2021 |
2021-12-22 | - | Extra Bolagsstämma 2021 |
2021-11-17 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2021-05-05 | - | Årsstämma |
2021-04-21 | - | Bokslutskommuniké 2020 |
2020-11-17 | - | Kvartalsrapport 2020-Q3 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-07-07 | - | Split NYKD 1:5 |
2020-07-06 | - | Extra Bolagsstämma |
2020-05-12 | - | Kvartalsrapport 2020-Q1 |
2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2023-05-11 11:10:18
Oslo, Norway, May 11, 2023 - The Annual General Meeting of Nykode Therapeutics
ASA was held May 11, 2023. All proposed resolutions on the agenda were approved
in accordance with the notice for the meeting published on April 20, 2023.
Minutes of the meeting are attached hereto.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which have been shown to induce
broad, strong and long-lasting antigen specific immune responses which
correlates with clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive safety and efficacy results from its Phase 2 trial for the
treatment of cervical cancer